An interventional study of Woodsmoke (Lodgepole Pine) exposure and Filtered air exposure in Asthma, Chronic Obstructive Pulmonary Disease (COPD) and Lung Cancer, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 19 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University of British Columbia · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Asthma by University of British Columbia — 5 open to participants now, 5 under way, none of them phase 3. Asthma · University of British Columbia.
Among the 20 studies in Asthma by University of British Columbia, this one is the 12th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2026, is one of 11 with no phase, and was the 19th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →5 of the 20 studies in Asthma by University of British Columbia are open now, in 1 country. Recruiting first, the newest first:
University of British Columbia · Sites in Canada
Ages up to 6 mo · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 18–55 · Healthy volunteers
University of British Columbia · Sites in Canada
Ages 19–49
University of British Columbia · Sites in Canada
Ages 18+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 19 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 24 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 52 across the 14 interventional studies, 511 across the 6 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of British Columbia is the lead sponsor of 1,342 studies on the registry; 262 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
1 of the studies in Asthma by University of British Columbia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07653347University of British ColumbiaInfant RSV Immunity Study | 2027-06-01 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies in Asthma by University of British Columbia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Wildfire smoke (WFS) is the leading climate-related risk in Canada and the main source of harmful air pollution. While short-term breathing problems caused by smoke are well known, there is limited knowledge on how repeated exposure contributes to long-term lung disease. This study is a controlled human exposure to varying concentrations of WFS in a safe setting. By comparing the effects of different concentrations, this research will improve understanding of health impacts, identify who may be most vulnerable to exposures, and explore biological changes that could lead to chronic illness.
PURPOSE: To use responses to controlled human exposures to woodsmoke, as a model of wildfire smoke (WFS), to quantify risk of, and add biological plausibility to, the supposition that WFS-related particulate matter with a diameter of 2.5 micrometers or less (PM2.5) contributes to the development of neurological and chronic lung diseases.
Study Exposure Arms:
Arm A: 3 consecutive days with 2h woodsmoke exposures at 35 µg/m3 of PM2.5 Arm B: 3 consecutive days with 2h woodsmoke exposures at 105 µg/m3 of PM2.5 Arm C: 2 consecutive days of Filtered Air (FA), followed by 1 day with a 2h woodsmoke exposure at 315 µg/m3 of PM2.5
HYPOTHESIS, JUSTIFICATIONS, AND OBJECTIVES Aim 1A: Enhance plausibility for, and quantify risk of, WFS contributions to chronic lung disease.
Hypothesis 1A: The investigators will determine mechanisms that plausibly link WFS exposure to the development of chronic disease, by connecting WFS exposures to lung function decline, asthma, chronic obstructive pulmonary disease (COPD), or lung cancer.
To assess the plausibility of linking WFS exposure to Chronic Lung Diseases such as asthma, COPD, and lung cancer.
To evaluate the biological impacts of WFS on the airways.
Aim 1B: Use a controlled human exposure study to identify, across different intensities of WFS exposure:
1.1 Neurocognitive changes relevant to the development of chronic neurological diseases 1.2 Temporal patterns of onset and resolution in relevant circulating neuro-inflammatory markers 1.3 Sex, age, and genetics as effect-modifying susceptibility factors for the above phenomena
Hypothesis 1B: The investigators will demonstrate disturbances in the brain default mode network (DMN), and intensity-dependent increases in circulating neuro-inflammatory markers, particularly in older individuals and those with genotypes conferring deficient anti-oxidant metabolism or those conferring risk of dementia.
RESEARCH DESIGN A randomized, double-blinded, crossover-controlled human exposure study.
STATISTICAL ANALYSIS Data will be analysed in R using generalized and linear mixed-effects models. Models will run with exposure as a fixed effect and participant ID as a random effect.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Three consecutive days with a 2-hour woodsmoke exposure at 35 µg/m3 of PM2.5 each day.
Other: Woodsmoke (Lodgepole Pine) exposure
Three consecutive days with a 2-hour woodsmoke exposure at 105 µg/m3 of PM2.5 each day.
Other: Woodsmoke (Lodgepole Pine) exposure
Two consecutive days of 2-hour filtered air exposures, followed by 1 day with a 2-hour woodsmoke exposure at 315 µg/m3 of PM2.5.
Other: Woodsmoke (Lodgepole Pine) exposure · Other: Filtered air exposure
Woodsmoke will be freshly generated using a furnace tube burning dried, ground lodgepole pine (Pinus contorta) to achieve the nominal PM2.5 (particulate matter with an aerodynamic diameter of less than or equal to 2.5 micrometres) concentrations specified for each study arm.
Exposures to HEPA filtered air, as a control.
Effects of PM2.5 exposures and concentration on exhaled nitric oxide.
Measurement of fractional exhaled nitric oxide (FeNO).
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on Cambridge Neuropsychological Test Automated Battery (CANTAB)
Computational testing using CANTAB to determine e.g. 5-choice reaction time and percent correct all delays.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on sputum cell numbers.
Differentially count sputum cells.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on brain functional connectivity.
Resting-state functional MRI (rs-fMRI) will assess functional connectivity within the default mode network (DMN) using a seed-based approach. Preprocessing will follow established neuroimaging methods. Functional connectivity will be determined as temporal correlations between blood-oxygen-level-dependent (BOLD) signal time series from a posterior cingulate cortex seed and DMN regions, using group-level statistical models.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on oxidative stress.
Assessment of oxidative stress using H2DCFDA.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on lung inflammatory markers.
An inflammation matrix will be generated, including data from RNA and protein inflammatory markers (e.g. interleukins (IL)-1ß, 4, 5, 6, 8, 9, 13, 17, 25 and 33, IFN., CSF1, TSLP, CC16/SCGB1A1 and c-reactive protein).
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on lung imaging.
The lungs will be imaged with hyperpolarized 129Xe gas to measure ventilation defect percent, membrane-to-gas ratio and red blood cell-to-gas ratio. These measures will be standardized and averaged to generate a single composite lung function imaging score per participant.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on circulating brain-derived biomarkers of neuroinflammation.
Analysis of circulating brain-derived biomarkers of neuroinflammation using the NULISAseq CNS Diesease Panel 120.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on neutrophil extracellular traps (NETs).
Analysis of counts of neutrophil extracellular traps (NETs).
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on host defence proteins.
Host defense peptides matrix, from e.g. alpha defensin-1, S100A7 and cystatin-SA.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on DNA methylation.
Measurement of DNA methylation after exposures and determination of epigenetic age.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on glia-derived extracellular vesicles.
Glia-derived extracellular vesicles will be measured in circulating blood using nanoflow cytometry-based direct labelling.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on breath volatile organic compounds.
Collection and analysis of breath volatiles using ReCIVA technology.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on airway microbial taxon abundance.
The airway microbiome will be characterized using sequencing. Differential abundance analysis will quantify changes in the relative abundance of individual airway microbial taxa across exposure conditions.
Time frame: Comparison of the different arms over the span of 4 months.
Effects of PM2.5 exposures and concentration on symptoms.
Symptoms and Perception questionnaires (e.g. https://particleandfibretoxicology.biomedcentral.com/articles/10.1186/s12989-022-00506-6#Sec15) will be completed.
Time frame: Comparison of the different arms over the span of 4 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Aug 2029, 39 months after the start.
Of 601 non-industry interventional studies with no phase under Asthma, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 50. This study's planned 39 months is above that.
Counting every sponsor, half of 651 studies reached it within 23 months; a quarter within 10 and three quarters within 47.
Start moved once since we started tracking on Sep 25, 2026: Apr 2026 → May 2026, on Oct 26, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of British Columbia →